- Home
- BLKB vs RNA Comparison
BLKB vs RNA Comparison
Compare BLKB & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLKB
- RNA
- Stock Information
- Founded
- BLKB 1981
- RNA 2012
- Country
- BLKB United States
- RNA United States
- Employees
- BLKB N/A
- RNA N/A
- Industry
- BLKB Computer Software: Prepackaged Software
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- BLKB Technology
- RNA Health Care
- Exchange
- BLKB Nasdaq
- RNA Nasdaq
- Market Cap
- BLKB 3.1B
- RNA 3.4B
- IPO Year
- BLKB 2004
- RNA 2020
- Fundamental
- Price
- BLKB $62.23
- RNA $33.17
- Analyst Decision
- BLKB Hold
- RNA Strong Buy
- Analyst Count
- BLKB 3
- RNA 12
- Target Price
- BLKB $78.67
- RNA $67.92
- AVG Volume (30 Days)
- BLKB 240.8K
- RNA 1.4M
- Earning Date
- BLKB 07-29-2025
- RNA 05-08-2025
- Dividend Yield
- BLKB N/A
- RNA N/A
- EPS Growth
- BLKB N/A
- RNA N/A
- EPS
- BLKB N/A
- RNA N/A
- Revenue
- BLKB $1,146,906,000.00
- RNA $8,927,000.00
- Revenue This Year
- BLKB N/A
- RNA N/A
- Revenue Next Year
- BLKB $4.03
- RNA $148.12
- P/E Ratio
- BLKB N/A
- RNA N/A
- Revenue Growth
- BLKB 2.13
- RNA N/A
- 52 Week Low
- BLKB $58.05
- RNA $21.51
- 52 Week High
- BLKB $88.95
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- BLKB 47.98
- RNA 61.28
- Support Level
- BLKB $60.75
- RNA $30.15
- Resistance Level
- BLKB $62.45
- RNA $32.09
- Average True Range (ATR)
- BLKB 0.99
- RNA 1.76
- MACD
- BLKB -0.12
- RNA 0.24
- Stochastic Oscillator
- BLKB 37.26
- RNA 98.40
About BLKB Blackbaud Inc.
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.